What You Should Know:
- Johns Hopkins University has signed an agreement with Rose Hill Life Sciences, a global leader in the research and intellectual property of premium psilocybin products to exclusively license intellectual property related to improving motor functions in patients with neurological injuries through the use of psychedelic therapy.
- The collaboration aims to explore the potential of psilocybin to enhance recovery from conditions such as
Read More
Psychedelic Healthcare
Cybin Raises $150M to Advance Psychedelic Therapy for Depression
What You Should Know:
- Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included participation from other institutional investors. The price per share was set at $0.43, representing a 17% premium over the 10-day volume-weighted average trading price.
- The funding will fuel the development of CYB003, a potential first-in-class psychedelic
Read More
Enthea Secures $2M to Expand Psychedelic Healthcare Provider Network
What You Should Know:
- Enthea, the first provider of insurance plans for psychedelic healthcare, has announced a $2M Seed Round raise led by Tabula Rasa Ventures to offer psychedelic-assisted therapy as a workplace benefit.
- The funds will be used to launch Enthea’s services into 40 markets across the U.S. in 2023 as well as grow its customer base and provider network to increase access to new, evidence-based healing options that have proven to be very effective in improving symptoms for
Read More
